Decreasing glioma recurrence through adjuvant cancer stem cell inhibition

Josh Neman, Rahul JandialDivision of Neurosurgery, City of Hope National Cancer Center, Duarte, CA, USAAbstract: Gliomas remain one of the most challenging solid organ tumors to treat and are marked clinically by invariable recurrence despite multimodal intervention (surgery, chemotherapy, radiation...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Josh Neman, Rahul Jandial
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/ff725080636c46bf8b798680ec23244e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ff725080636c46bf8b798680ec23244e
record_format	dspace
spelling	oai:doaj.org-article:ff725080636c46bf8b798680ec23244e2021-12-02T02:26:59ZDecreasing glioma recurrence through adjuvant cancer stem cell inhibition1177-54751177-5491https://doaj.org/article/ff725080636c46bf8b798680ec23244e2010-06-01T00:00:00Zhttp://www.dovepress.com/decreasing-glioma-recurrence-through-adjuvant-cancer-stem-cell-inhibit-a4644https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Josh Neman, Rahul JandialDivision of Neurosurgery, City of Hope National Cancer Center, Duarte, CA, USAAbstract: Gliomas remain one of the most challenging solid organ tumors to treat and are marked clinically by invariable recurrence despite multimodal intervention (surgery, chemotherapy, radiation). This recurrence perhaps, is as a consequence of the failure to eradicate a tumor cell subpopulation, termed cancer stem cells. Isolating, characterizing, and understanding these tumor-initiating cells through cellular and molecular markers, along with genetic and epigenetic understanding will allow for selective targeting through therapeutic agents and holds promise for decreasing glioma recurrence.Keywords: glioma, cancer stem cells, epigenetic Josh NemanRahul JandialDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2010, Iss default, Pp 157-162 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Josh Neman Rahul Jandial Decreasing glioma recurrence through adjuvant cancer stem cell inhibition
description	Josh Neman, Rahul JandialDivision of Neurosurgery, City of Hope National Cancer Center, Duarte, CA, USAAbstract: Gliomas remain one of the most challenging solid organ tumors to treat and are marked clinically by invariable recurrence despite multimodal intervention (surgery, chemotherapy, radiation). This recurrence perhaps, is as a consequence of the failure to eradicate a tumor cell subpopulation, termed cancer stem cells. Isolating, characterizing, and understanding these tumor-initiating cells through cellular and molecular markers, along with genetic and epigenetic understanding will allow for selective targeting through therapeutic agents and holds promise for decreasing glioma recurrence.Keywords: glioma, cancer stem cells, epigenetic
format	article
author	Josh Neman Rahul Jandial
author_facet	Josh Neman Rahul Jandial
author_sort	Josh Neman
title	Decreasing glioma recurrence through adjuvant cancer stem cell inhibition
title_short	Decreasing glioma recurrence through adjuvant cancer stem cell inhibition
title_full	Decreasing glioma recurrence through adjuvant cancer stem cell inhibition
title_fullStr	Decreasing glioma recurrence through adjuvant cancer stem cell inhibition
title_full_unstemmed	Decreasing glioma recurrence through adjuvant cancer stem cell inhibition
title_sort	decreasing glioma recurrence through adjuvant cancer stem cell inhibition
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/ff725080636c46bf8b798680ec23244e
work_keys_str_mv	AT joshneman decreasinggliomarecurrencethroughadjuvantcancerstemcellinhibition AT rahuljandial decreasinggliomarecurrencethroughadjuvantcancerstemcellinhibition
_version_	1718402508028641280

Decreasing glioma recurrence through adjuvant cancer stem cell inhibition

Ejemplares similares